Chia-Wei Li
YOU?
Author Swipe
View article: DDX3 regulates cancer immune surveillance via 3′ UTR-mediated cell-surface expression of PD-L1
DDX3 regulates cancer immune surveillance via 3′ UTR-mediated cell-surface expression of PD-L1 Open
Programmed death-1 (PD-1)/PD ligand-1 (PD-L1)-mediated immune escape contributes to cancer development and has been targeted as an anti-cancer strategy. Here, we show that inhibition of the RNA helicase DDX3 increased CD8+ T cell infiltrat…
View article: Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer
Genetic insights into carbohydrate sulfotransferase 8 and its impact on the immunotherapy efficacy of cancer Open
Immune checkpoint blockade (ICB) is a promising therapy for solid tumors, but its effectiveness depends on biomarkers that are not precise. Here, we utilized genome-wide association study to investigate the association between genetic vari…
View article: Supplementary Materials and Methods from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer
Supplementary Materials and Methods from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer Open
Supplementary Materials and Methods
View article: Data from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer
Data from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer Open
miR-200c is a tumor suppressor miRNA that plays a critical role in regulating epithelial phenotype and cancer stemness. p53 deficiency downregulates the expression of miR-200c and leads to epithelial-mesenchymal transition (EMT) and stemne…
View article: Supplementary Figure 1-14 from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer
Supplementary Figure 1-14 from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer Open
S1. miR-200c-deficiency induced biological effects in mammary epithelial cells. S2. Expression of EMT inducers and stemness genes in miR-200c KO or overexpressing cells. S3. miR-200c-deficiency induces Warburg effect in mammary epithelial …
View article: Data from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer
Data from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer Open
miR-200c is a tumor suppressor miRNA that plays a critical role in regulating epithelial phenotype and cancer stemness. p53 deficiency downregulates the expression of miR-200c and leads to epithelial-mesenchymal transition (EMT) and stemne…
View article: Supplementary Figure 1-14 from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer
Supplementary Figure 1-14 from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer Open
S1. miR-200c-deficiency induced biological effects in mammary epithelial cells. S2. Expression of EMT inducers and stemness genes in miR-200c KO or overexpressing cells. S3. miR-200c-deficiency induces Warburg effect in mammary epithelial …
View article: Supplementary Materials and Methods from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer
Supplementary Materials and Methods from Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c–PCK2 Axis in Basal-Like Breast Cancer Open
Supplementary Materials and Methods
View article: Data from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Data from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation Open
The oncogenic transcription factor Gli1 is a critical effector in the Hedgehog (Hh) pathway, which is necessary for the development and progression of pancreatic ductal adenocarcinoma (PDAC). Although TGFβ and K-Ras are known regulators of…
View article: Supplementary Movie S1 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S1 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment inhibits cell proliferation of MDA-MB-231 cells. Time-lapse video of 231 (Nuc-RFP) cells without olaparib (control) taken using the IncuCyte Zoom microscope.
View article: Supplementary Movie S4 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S4 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment enhances resistance to activated T-cell killing. Time-lapse video of 231 (Nuc-RFP) cells with olaparib treatment co-cultured with activated PBMCs taken using the IncuCyte Zoom microscope.
View article: Supplementary Movie S4 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S4 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment enhances resistance to activated T-cell killing. Time-lapse video of 231 (Nuc-RFP) cells with olaparib treatment co-cultured with activated PBMCs taken using the IncuCyte Zoom microscope.
View article: Supplementary Tables from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection
Supplementary Tables from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection Open
Supplementary Table S1. List of antibodies used for the immunoblotting, immunofluorescence, and immunohistochemistry. Supplementary Table S2. List of inhibitors used in this study with stock concentration and dilution. Supplementary Table …
View article: Supplemental Information from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplemental Information from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
Supplementary Figure S1. PARPi upregulates PD-L1 in a dose-dependent manner in MD-MB-231 cells. Supplementary Figure S2. Downregulation of BRCA1 or BRCA2 has no effect on PARPi-induced PD-L1 upregulation. Supplementary Figure S3. PARPi ina…
View article: Supplementary Figures S1-S5 from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Supplementary Figures S1-S5 from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation Open
Correlation between Gli1 and PRMT1 Levels (S1); Identification of a PRMT1-Methylated Site in Gli1 (S2); Effects of R597 on Gli1 Transcriptional Activity (S3); Tumorigenicity of Wild-Type Gli1 and R597K-Mutated Gli1 (S4); Regulation of Gli1…
View article: Supplementary Movie S1 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S1 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment inhibits cell proliferation of MDA-MB-231 cells. Time-lapse video of 231 (Nuc-RFP) cells without olaparib (control) taken using the IncuCyte Zoom microscope.
View article: Supplementary Figures S1-S5 from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Supplementary Figures S1-S5 from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation Open
Correlation between Gli1 and PRMT1 Levels (S1); Identification of a PRMT1-Methylated Site in Gli1 (S2); Effects of R597 on Gli1 Transcriptional Activity (S3); Tumorigenicity of Wild-Type Gli1 and R597K-Mutated Gli1 (S4); Regulation of Gli1…
View article: Supplementary Methods and References from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Supplementary Methods and References from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation Open
Description of additional methods and procedures used in the study. Also includes Supplementary References.
View article: Supplementary Methods and References from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Supplementary Methods and References from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation Open
Description of additional methods and procedures used in the study. Also includes Supplementary References.
View article: Supplemental Information from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplemental Information from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
Supplementary Figure S1. PARPi upregulates PD-L1 in a dose-dependent manner in MD-MB-231 cells. Supplementary Figure S2. Downregulation of BRCA1 or BRCA2 has no effect on PARPi-induced PD-L1 upregulation. Supplementary Figure S3. PARPi ina…
View article: Supplementary Movie S2 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S2 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment inhibits cell proliferation of MDA-MB-231 cells. Time-lapse video of 231 (Nuc-RFP) cells with olaparib taken using the IncuCyte Zoom microscope.
View article: Supplementary Table S1 from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation
Supplementary Table S1 from Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation Open
Gli1-binding proteins identified through mass spectrum.
View article: Supplementary Movie S3 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S3 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment enhances resistance to activated T-cell killing. Time-lapse video of 231 (Nuc-RFP) cells without olaparib treatment (control) co-cultured with activated PBMCs taken using the IncuCyte Zoom microscope.
View article: Data from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Data from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP inhibitor (PARPi) in tumor suppression.Experimental Design: Breast…
View article: Supplementary Movie S3 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S3 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment enhances resistance to activated T-cell killing. Time-lapse video of 231 (Nuc-RFP) cells without olaparib treatment (control) co-cultured with activated PBMCs taken using the IncuCyte Zoom microscope.
View article: Supplementary Figures from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection
Supplementary Figures from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection Open
Supplementary Figure S1. Immunoblot and heatmap of EMT regulators in HCC. Supplementary Figure S2. immunofluorescence, immunoblot, and cell counting of HCC cells with or without Snail knockdown. Supplementary Figure S3. Identification of T…
View article: Supplementary Tables from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection
Supplementary Tables from Severe Hepatitis Promotes Hepatocellular Carcinoma Recurrence via NF-κB Pathway-Mediated Epithelial–Mesenchymal Transition after Resection Open
Supplementary Table S1. List of antibodies used for the immunoblotting, immunofluorescence, and immunohistochemistry. Supplementary Table S2. List of inhibitors used in this study with stock concentration and dilution. Supplementary Table …
View article: Supplementary Movie S2 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Supplementary Movie S2 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
PARPi treatment inhibits cell proliferation of MDA-MB-231 cells. Time-lapse video of 231 (Nuc-RFP) cells with olaparib taken using the IncuCyte Zoom microscope.
View article: Data from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Data from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression Open
Purpose: To explore whether a cross-talk exists between PARP inhibition and PD-L1/PD-1 immune checkpoint axis, and determine whether blockade of PD-L1/PD-1 potentiates PARP inhibitor (PARPi) in tumor suppression.Experimental Design: Breast…